David Martin PhD
Stock Analyst at Bloom Burton
(4.69)
# 745
Out of 4,334 analysts
218
Total ratings
51.4%
Success rate
16.7%
Average return
Main Sectors:
Stocks Rated by David Martin PhD
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: HLS HLS Therapeutics Inc. | Maintained: Buy | $12 | $4.65 | +158.06% | 50 | May 19, 2026 | |
| TSX: MBX Microbix Biosystems Inc. | Maintained: Buy | $0.5 → $0.4 | $0.26 | +53.85% | 13 | May 15, 2026 | |
| TSXV: RX BioSyent Inc. | Maintained: Buy | $17 | $13.76 | +19.91% | 13 | May 15, 2026 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Hold | $15 | $15.22 | -1.45% | 33 | May 11, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Maintained: Buy | $11 → $12 | $8.36 | +43.54% | 28 | May 8, 2026 | |
| TSX: CRRX CareRx Corporation | Maintained: Buy | $5.5 → $5 | $3.47 | +44.09% | 11 | May 8, 2026 | |
| ZYME Zymeworks | Maintained: Buy | $35 | $25.61 | +36.67% | 12 | Apr 27, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $14 | $10.24 | +36.72% | 5 | Apr 27, 2026 | |
| ASX: PYC PYC Therapeutics Limited | Maintained: Buy | $4 → $5 | $1.34 | +273.13% | 3 | Mar 19, 2026 | |
| XENE Xenon Pharmaceuticals | Maintained: Buy | $57 → $74 | $54.17 | +36.61% | 8 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 | $4.68 | +904.27% | 7 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $4.05 | +48.15% | 12 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $4 | $0.45 | +788.89% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $5.20 | +73.08% | 6 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $17.24 | +14.27% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $19 | $16.93 | +12.23% | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $1 | $0.27000001 | +270.37% | 2 | Jul 6, 2025 |
HLS Therapeutics Inc.
May 19, 2026
Maintained: Buy
Price Target: $12
Current: $4.65
Upside: +158.06%
Microbix Biosystems Inc.
May 15, 2026
Maintained: Buy
Price Target: $0.5 → $0.4
Current: $0.26
Upside: +53.85%
BioSyent Inc.
May 15, 2026
Maintained: Buy
Price Target: $17
Current: $13.76
Upside: +19.91%
Aurinia Pharmaceuticals
May 11, 2026
Maintained: Hold
Price Target: $15
Current: $15.22
Upside: -1.45%
Knight Therapeutics Inc.
May 8, 2026
Maintained: Buy
Price Target: $11 → $12
Current: $8.36
Upside: +43.54%
CareRx Corporation
May 8, 2026
Maintained: Buy
Price Target: $5.5 → $5
Current: $3.47
Upside: +44.09%
Zymeworks
Apr 27, 2026
Maintained: Buy
Price Target: $35
Current: $25.61
Upside: +36.67%
Eupraxia Pharmaceuticals Inc.
Apr 27, 2026
Maintained: Buy
Price Target: $14
Current: $10.24
Upside: +36.72%
PYC Therapeutics Limited
Mar 19, 2026
Maintained: Buy
Price Target: $4 → $5
Current: $1.34
Upside: +273.13%
Xenon Pharmaceuticals
Mar 9, 2026
Maintained: Buy
Price Target: $57 → $74
Current: $54.17
Upside: +36.61%
Mar 5, 2026
Maintained: Buy
Price Target: $47
Current: $4.68
Upside: +904.27%
Feb 13, 2026
Maintained: Buy
Price Target: $6
Current: $4.05
Upside: +48.15%
Dec 11, 2025
Maintained: Buy
Price Target: $6 → $4
Current: $0.45
Upside: +788.89%
Nov 19, 2025
Maintained: Buy
Price Target: $9
Current: $5.20
Upside: +73.08%
Oct 21, 2025
Maintained: Buy
Price Target: $20
Current: $17.24
Upside: +14.27%
Jul 18, 2025
Maintained: Buy
Price Target: $20 → $19
Current: $16.93
Upside: +12.23%
Jul 6, 2025
Initiated Coverage: Buy
Price Target: $1
Current: $0.27000001
Upside: +270.37%